Advanced CSCC


Proven efficacy in patients with advanced CSCC who received LIBTAYO in Study 15401,2*

Response rates in patients with mCSCC or laCSCC who were not candidates for curative surgery or curative radiation1

Tumor response assessment, time to response and duration of response with LIBTAYO

Median follow-up duration1:

  • mCSCC group: 16.5 months
  • laCSCC group: 9.3 months
  • Combined advanced CSCC group: 11.1 months
  • mCSCC LIBTAYO 350 mg Q3W group: 8.0 months

Median TTR1,2:

  • Combined advanced CSCC group: 1.9 months (range, 1.7-9.1 months)
  • mCSCC LIBTAYO 350 mg Q3W group: 2.1 months (range, 2.0-8.3 months)
  • *Data cutoff was September/October 2018.2
  • The numerator includes the number of patients whose observed DOR reached at least the specified times of 6 or 12 months. Patients who did not have the opportunity to reach the specified time point were included in the denominator only.1
  • Plus sign (+) denotes ongoing at last assessment.1
  • CR=complete response; CSCC=cutaneous squamous cell carcinoma; laCSCC=locally advanced CSCC; mCSCC=metastatic CSCC; NE=not evaluable; NR=not reached; Q2W=every 2 weeks; Q3W=every 3 weeks; TTR=time to response

The recommended dosage of LIBTAYO is 350 mg administered as an intravenous infusion over 30 minutes every 3 weeks until disease progression or unacceptable toxicity.1

Cemiplimab-rwlc (LIBTAYO®) Clinical Trial Designs, Results, and Safety Data

Medical oncologist Dr Ezra Cohen covers the LIBTAYO clinical trial results, presents patient screening images, discusses NCCN Guidelines Recommendations, and shares safety data, including the serious and most common adverse reactions for LIBTAYO.
Please click here for full Prescribing Information.